Search Results
Your search for ,iII matches 9386 pages
Showing 51 - 100ASCO Congratulates 2026 Special Award Recipients
ASCO and Conquer Cancer, the ASCO Foundation, are proud to celebrate a distinguished group of individuals at the 2026 ASCO Annual Meeting. The Society will present its highest honors to researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous ...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
Real-world data suggest that GLP-1 receptor agonists (RAs) may reduce metastatic progression in certain obesity-related cancers, particularly lung, breast, colorectal, and liver cancers, according to findings to be presented at the 2026 ASCO Annual Meeting (Abstract 3143). GLP-1 receptor expression ...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial that will be presented at the 2026 ASCO Annual Meeting (Abstract 12004). The analysis also suggested that...
Losing Weight, Gaining Quality of Life in Early-Stage Breast Cancer
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Vicini et al, the phase III NRG/RTOG 1005 trial has shown noninferior risk for ipsilateral breast recurrence (IBR) with concurrent vs sequential radiation dose escalation to the surgical cavity in conservative treatment of high-risk early breast...
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
In a phase I/II trial (RMC-6236-001) reported in The New England Journal of Medicine, Wolpin et al identified the safety profile of daraxonrasib and showed activity of the agent in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib (RMC-6236) ...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC
As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent...
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
On May 1, the U.S. Food and Drug Administration announced that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib. In mid-April, Revolution Medicines...
On-Treatment PSA and Overall Survival in Prostate Cancer
In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE...
FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ...
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up From AUGMENT
As reported in the Journal of Clinical Oncology by Leonard et al, the 5-year follow-up of the phase III AUGMENT trial has shown continued benefit of lenalidomide plus rituximab (R2) vs rituximab with placebo (R-placebo) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder cancer (MIBC), allowing many patients to potentially avoid cystectomy, according to the results of a...
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy in patients with chemorefractory RAS/BRAF wild-type metastatic colorectal cancer. Study Details In...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...
Metastatic NSCLC: Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Romiplostim for Chemotherapy-Induced Thrombocytopenia
In a phase III trial (RECITE) reported in The New England Journal of Medicine, Al-Samkari et al found that the thrombopoietin receptor agonist romiplostim was effective in treating chemotherapy-induced thrombocytopenia (CIT) among patients receiving oxaliplatin-based multiagent cytotoxic...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
Case 1: RCC With Disease Progression After Adjuvant Pembrolizumab
This is Part 1 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of renal cell carcinoma...
Colorectal Cancer: Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy
The antidepressant duloxetine was unable to prevent sensory oxaliplatin-induced peripheral neuropathy more significantly than placebo in patients with colorectal cancer receiving chemotherapy, according to the results of the Alliance A221805 trial published in JCO Oncology Advances. “Since we know ...
Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen...
IMPT vs IMRT in Oropharyngeal Cancer
As reported in The Lancet by Thomson et al, the UK phase III TORPEdO trial has shown similar outcomes with intensity-modulated proton therapy (IMPT) vs intensity-modulated radiation therapy (IMRT) in patients with locally advanced oropharyngeal squamous cell carcinoma. Study Details In the...
Metastatic Papillary Renal Cancer: Final Results With Savolitinib and Durvalumab
As reported in the Journal of Clinical Oncology by Jackson-Spence et al, final results of the phase II CALYPSO study indicated better overall survival and other outcomes with savolitinib and durvalumab among patients with metastatic papillary renal cancer who have MET-driven disease. Study...
Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Conflict
A new analysis from Phesi, a data analytics company, of 65,061 globally recruiting clinical trials across 186 countries has found that 4,361 studies—equivalent to 6.7% of all active trials—are impacted by disruption in the Middle East. Across a total of 356,699 recruiting investigator sites, 7,958...
Financial Hardship and Late-Stage Cancer Diagnosis
In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with organized screening programs and those detectable via physical examination. Study Details The...
Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
As reported in The New England Journal of Medicine by Langley et al, a UK phase III trial (PATCH/STAMPEDE-1) has shown noninferiority in metastasis-free survival with the use of transdermal estradiol (tE2) patches vs luteinizing hormone–releasing hormone (LHRH) agonist treatment in men with locally ...
Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment
In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting most from the addition of PD-1 inhibition to chemoradiotherapy (CRT) in locoregionally advanced...
